

Citation: Habicher J, Haitina T, Eriksson I, Holmborn K, Dierker T, Ahlberg PE, et al. (2015) Chondroitin / Dermatan Sulfate Modification Enzymes in Zebrafish Development. PLoS ONE 10(3): e0121957. doi:10.1371/journal.pone.0121957

Academic Editor: Xin Zhang, Columbia University, UNITED STATES

Received: September 17, 2014

Accepted: February 8, 2015

Published: March 20, 2015

Copyright: © 2015 Habicher et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by grants from the Knut and Alice Wallenberg Foundation (https:// www.wallenberg.com/kaw/en), and the Swedish Research Council VR (http://www.vr.se/inenglish.4. 12fff4451215cbd83e4800015152.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

RESEARCH ARTICLE

Chondroitin / Dermatan Sulfate Modification Enzymes in Zebrafish Development

Judith Habicher¹, Tatjana Haitina¹, Inger Eriksson², Katarina Holmborn¹, Tabea Dierker², Per E. Ahlberg¹, Johan Ledin¹*

Department of Organismal Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden,
Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

* Johan.Ledin@ebc.uu.se

Abstract

Chondroitin/dermatan sulfate (CS/DS) proteoglycans consist of unbranched sulfated polysaccharide chains of repeating GalNAc-GlcA/IdoA disaccharide units, attached to serine residues on specific proteins. The CS/DS proteoglycans are abundant in the extracellular matrix where they have essential functions in tissue development and homeostasis. In this report a phylogenetic analysis of vertebrate genes coding for the enzymes that modify CS/DS is presented. We identify single orthologous genes in the zebrafish genome for the sulfotransferases chst7, chst11, chst13, chst14, chst15 and ust and the epimerase dse. In contrast, two copies were found for mammalian sulfotransferases CHST3 and CHST12 and the epimerase DSEL, named chst3a and chst3b, chst12a and chst12b, dsela and dselb, respectively. Expression of CS/DS modification enzymes is spatially and temporally regulated with a large variation between different genes. We found that CS/DS 4-O-sulfotransferases and 6-O-sulfotransferases as well as CS/DS epimerases show a strong and partly overlapping expression, whereas the expression is restricted for enzymes with ability to synthesize di-sulfated disaccharides. A structural analysis further showed that CS/DS sulfation increases during embryonic development mainly due to synthesis of 4-O-sulfated GalNAc while the proportion of 6-O-sulfated GalNAc increases in later developmental stages. Di-sulfated GalNAc synthesized by Chst15 and 2-O-sulfated GlcA/IdoA synthesized by Ust are rare, in accordance with the restricted expression of these enzymes. We also compared CS/DS composition with that of heparan sulfate (HS). Notably, CS/DS biosynthesis in early zebrafish development is more dynamic than HS biosynthesis. Furthermore, HS contains disaccharides with more than one sulfate group, which are virtually absent in CS/DS.

Introduction

Chondroitin/dermatan sulfate (CS/DS) proteoglycans consist of core proteins with attached linear sulfated polysaccharides of repeating glucuronic acid and *N*-acetylgalacotsamine (GlcA--GalNAc) in CS or iduronic acid and *N*-acetylgalactosamine (IdoA-GalNAc) in DS (Fig. 1). CS/DS is produced by virtually all vertebrate cells and has multiple functions during animal development, including fundamental processes as cell division and cytokinesis [1–3]. CS/DS is



Fig 1. Modification reactions in CS/DS biosynthesis. The CS/DS chain is modified by sulfotransferases and epimerases. A GlcNAc added to the linkage region (asterisk) commits the nascent chain to HS synthesis instead of CS/DS synthesis. Epi: GlcA-C5-epimerase, Gal: galactose, GalNAc: *N*-Acetylgalcotamine, GlcA: glucuronic acid, GlcNAc: *N*-Acetylglucosamine, IdoA: iduronic acid, Ser: Serine, Xyl: xylose, 2-O-ST: 2-O-sulfotransferase, 4-O-ST: 4-O-sulfotranferases, 4S-6ST: *N*-Acetylgalactosamine-4-sulfate-6-O-sulfotransferase, 6-O-ST: 6-O-sulfotransferases.

deposited extensively in cartilage ECM, where the high overall charge provides electrostatic forces to promote high water content, enabling joints to withstand mechanical compression. CS/DS biosynthesis produces chains varying in length, charge density and sulfation pattern, which affect physical docking to ECM molecules, such as growth factors, thus functioning as an extra level of regulation to dictate the function of CS/DS binding proteins [4, 5].

The biosynthesis of CS/DS is initiated with the synthesis of a GlcA–Gal–Gal–Xyl–O-Ser tetrasaccharide structure attached to one of more than 30 known CS/DS core proteins [5, 6]. This structure constitutes the linkage region for CS/DS as well as for heparan sulfate (HS). In HS biosynthesis, a GlcNAc is added to the linkage region as the fifth sugar followed by repeating additions of GlcNAc and GlcA. In biosynthesis of CS/DS a GalNAc is added to the linkage region (Fig. 1). Sometimes there may be a competition for link structures by CS/DS and HS specific enzymes [7]. However, if HS or CS will be synthesized also depends on other factors such as amino acid properties in close vicinity to the attachment serine residue [8] and sulfation of the link structure [9]. Elongation of CS/DS by repeating additions of GalNAc and GlcA is the result of a concerted action of CS/DS glycosyltransferases [5, 6, 10].

The common sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS) is used by all sulfotransferases during CS/DS modification. CS modifications are initiated by the addition of a sulfate group to the GalNAc C-4 or C-6 position by chondroitin 4-O- or 6-O-sulfotransferases, respectively (Fig. 1). A portion of GlcA residues are converted by DS epimerases to IdoA, and IdoA-GalNAc disaccharides may be sulfated on the C-4 position of the GalNAc residue by a dermatan 4-O-sulfotransferase. Subsequently, a subset of 4-O-sulfated or 6-O-sulfated disaccharides may be disulfated by the sulfation of the C-2 position on GlcA/IdoA by a 2-O-sulfotransferase or sulfated at the C-6 position of a previously C-4 sulfated GalNAc residue by a GalNAc4S-6-O-sulfotransferase. Typically, the resulting molecule consists of both GlcA and IdoA residues and is hence a hybrid between CS and DS.

Eight CS/DS sulfotransferases were identified in mammals: two chondroitin 6-O-sulfotransferases CHST3 (C6ST-1) [11] and CHST7 (C6ST-2) [12], three chondroitin 4-O-sulfotransferases CHST11 (C4ST-1) [13], CHST12 (C4ST-2) [13], CHST13 (C4ST-3) [14], one dermatan 4-O-sulfotransferase CHST14 (D4ST-1) [15], one N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase CHST15 (GALNAC4S-6ST) [16] and one uronyl-2-sulfotransferase (UST) [17]. Conversion of GlcA residues into the stereoisomer IdoA is mediated by two dermatan sulfate epimerases, DSE (DS-epi1) [18] and DSEL (DS-epi2) [19].

A number of genetic alterations in genes involved in the CS/DS biosynthesis have been investigated in human patients [20] transgenic mice [21]. Human patients with mutations in the

chondroitin 6-O-sulfotransferase CHST3 gene develop chondrodysplasia and are diagnosed with Larsen syndrome [22, 23], although targeted mutations in the *Chst3* gene in mice did not result in any apparent phenotype [24]. Different homozygous mutations in human CHST14 and *DSE* have been linked to Ehlers-Danlos syndrome (EDS), where patients display, among other symptoms, distinctive craniofacial dysmorphism [25, 26]. Mice lacking a functional *Chst14* or *Dse* gene have a reduced body size and show increased skin fragility, corresponding to human symptoms [25, 27]. A lower survival frequency of these mice has also been seen. Interestingly, a genome-wide association study suggested CHST11 as a plausible candidate gene for increased osteoarthritis susceptibility [28]. Mice lacking functional *Chst11* (*C4ST-1*) develop chondrodysplasia [5, 29] while mice deficient of functional *Chst15* (*GalNac4S-6ST*) lack GalNAc 4,6 disulfate residues but develop no apparent abnormalities [30].

In the developing mouse embryo *chst11* is expressed in the branchial arches and the limb buds as well as in the notochord [<u>31</u>]. *Chst12 (C4ST-2)* is expressed in the stomach and gut as well as in the skeleton in a 14,5 day old mouse embryo [<u>32</u>]. *Chst13 (C4ST-3)* is expressed in the liver and kidney, in the bones of the upper and lower jaws and in the eye socket [<u>33</u>]. No expression was found in the developing brain, in contrast to adult brain *Chst13* expression. *Chst15* is expressed during mouse embryonic development at E8.5 in the neuroepithelium of the forebrain region, and is particularly strong in the dorsal aspects of the neural folds [<u>22</u>]. Furthermore, expression was detected in the pharyngeal region and the foregut as well as in the somites [<u>22</u>].

Little is known of the spatio-temporal regulation of CS/DS biosynthesis during zebrafish development. Hayes and coworkers have used antibodies recognizing CS/DS sulfation motifs to study zebrafish skeletogenesis, and describe non-sulfated disaccharides and disaccharides with sulfate groups at C-4 and C-6 positions (Fig. 1), but also more subtle changes in sulfation pattern indicating dynamic control of CS/DS biosynthesis during development [34]. Expression of CS/DS modification enzymes during zebrafish embryonic development has not been systematically studied but a study of zebrafish *chst11* (*C4ST-1*) shows persistent expression in somites and brain, and transient expression in the pectoral fins [35].

We have previously characterized CS/DS polymerization during zebrafish development [10] and in this study we systematically investigate the phylogeny and expression of all known CS/DS modification enzymes as well as the temporal variation of CS/DS structures. We conclude that CS/DS biosynthesis is a highly dynamic regulated process during vertebrate development.

Experimental Procedure

Ethic statement

All animal experiments in this project were approved by Uppsala Djurförsöksetiska nämnd, Uppsala, Sweden (Permit number C262/11).

Animals

Wild-type zebrafish (AB, WIK) embryos were obtained in natural crosses and cultured in system water. 0.003% 1-phenyl-2-thiourea (Sigma) was added to the water to inhibit pigmentation. Embryos were anesthetized in tricaine methanesulfonate (Sigma-Aldrich) prior to fixation and staged using hours post fertilization (hpf) [36].

Phylogenetic analysis

Gene and protein sequences for CHST3, CHST7, CHST11–15, UST, DSE, and DSEL from human, mouse, zebrafish and stickleback were collected from the Ensembl database [<u>37</u>]. Ensembl accession numbers are displayed in <u>Table 1</u>. Amino acid sequences were aligned with

| Memory Memory Methods Carbon Methods Evenolity for the semiolity for the semiolit | HumariAlternative nameEnsembl NrMouseChondroitin 6-O-1228631CHST3Chondroitin 6-O-1228631Sulfotransferase 114711911CHST1Chondroitin 4-O-1713101CHST12Sulfotransferase 11713101CHST12Chondroitin 4-O-1713101CHST13Chondroitin 4-O-1362131CHST13Chondroitin 4-O-1362131CHST14Dermatan1691051CHST15N-1807671CHST16Sulfotransferase 21807671CHST17Chondroitin 4-O-1362131CHST18Chondroitin 4-O-1362131CHST18Chondroitin 4-O-1362131Ufotransferase 218076711CHST18Chondroitin 4-O-1807671CHST18Chondroitin 4-O-1807671Ufotransferase 3110511CHST18N-1807671CHST18N-1807671CHST18Chondroitin 4-O-1807671CHST18N-1807671CHST18N-1807671CHST18N-1807671CHST18N-1807671Ufotransferase1807671CHST18N-1CHST18N-1Ufotransferase1DS/CS 2-O1CHONDA | r Chr. Pos. 0 10:73.72m | Ensembl Nr | Chr. Pos. | Zebrafish | aa | Ensembl Nr | Chr. Pos. | Stickleback | Ensembl Nr | 04, Doc |
|--|---|--------------------------------------|---------------|---------------|---------------------|------|--------------|---------------|-------------|---------------|----------------|
| Obtool Controline i-C, image Control image | CHST3 Chondrotitn 6-0- sulfotransferase 1 6-sulfotransferase 2 6-sulfotransferase 2 6-sulfotransferase 2 CHST1 Chondrotitn 4-0- sulfotransferase 2 CHST13 Chondrotitn 4-0- sulfotransferase 3 Sulfotransferase 3 CHST14 Dermatan CHST15 N- CHST15 N- UICT I130CS 2-0 UIST DS/CS 2-0 UIST DS/CS 2-0 UIST DS/CS 2-0 UIST DS/CS 2-0 UIST DS/CS 2-0 Sulfotransferase 1 111817 | 10:73.72m | ENSMUSG000000 | | | % | ENSDARG00000 | | | ENSGACG000000 | CIII. TOS. |
| Alternational control of the conttrol of the control of the control of the control of th | CHST7 Chondroitin 147119 5 6-sulfotransferase 2 CHST1 Chondroitin 4-O- 171310 1 sulfotransferase 1 17310 1 CHST12 Chondroitin 4-O- 136213 1 sulfotransferase 2 sulfotransferase 2 180767 1 sulfotransferase 3 CHST13 Chondroitin 4-O- 180767 1 sulfotransferase 3 CHST14 Dermatan 169105 CHST15 N- 182022 CHST15 N- 1820 | | 57337 | 10: 60.18m | chst3a | 58 | 61070 | 13: 29.74m | chst3a | 02438 | grV:1.01m |
| GHT Controlmedianes T/11 X46.46m 3747 X20.06m 61471 73 4333 4341 63757m 61471 1383 9101 CHT1 Controlmin-40. 17310 21.04.65m 461 26 26.36m 6411 79 4373 6417 1390 6417 9401 9410 | CHST7 Chondroitin 147119 5-sulfotransferase 2 CHST11 Chondroitin 4-O- 171310 17310 Sulfotransferase 1 sulfotransferase 1 17310 17310 CHST12 Chondroitin 4-O- 136213 1 CHST12 Chondroitin 4-O- 136213 1 CHST13 Chondroitin 4-O- 136213 1 Sulfotransferase 2 136213 1 1 Sulfotransferase 2 136213 1 1 CHST13 Chondroitin 4-O- 136213 1 CHST14 Chondroitin 4-O- 180767 1 CHST15 N- 180767 1 CHST15 N- 182022 1 CHST15 N- 182022 1 UST N- 182022 1 1 UST DS/CS 2-O 111962 1 1 Sulfotransferase Sulfotransferase 111817 1 Sulfotransferase Sulfotransferase 111817 1 Sulfotransferase 111962 1 1 1 | | | | chst3b | 23 | 77844 | 12: 50.62m | chst3b | 08386 | grVI:9.61m |
| CHST1 Concritent +0. T/310 2:104.66m 3612 0.6411 7.9 3475 4.8.24m 6111 9340 9103 CHST2 Chordroint +0. 13621 7:24m 3699 5. 4112 6112 5 7130 6112 6792 9104 CHST2 Chordroint +0. 13621 7:24m 3599 5. 4112 6121 6 7130 6112 6792 9104 CHST2 Chordroint +0. 13621 7:24m 3599 5. 4113 6111 613 911 6113 6113 6111 6113 </td <td>CHST11 Chondroitin 4-0- sulfotransferase 1 171310 CHST12 Chondroitin 4-0- sulfotransferase 2 136213 CHST13 Chondroitin 4-0- sulfotransferase 3 180767 CHST14 Dermatan 169105 CHST15 N- sulfotransferase 1 182022 CHST15 N- sulfotransferase 1 182022 CHST15 N- sulfotransferase 111962 UST DS/CS 2-0 111962 DSE Chondroitin- sulfotransferase 111962</td> <td>X:46.43m</td> <td>37347</td> <td>X: 20.06m</td> <td>chst7</td> <td>53</td> <td>44341</td> <td>6: 37.57m</td> <td>chst7</td> <td>13833</td> <td>grVIII:17.98m</td> | CHST11 Chondroitin 4-0- sulfotransferase 1 171310 CHST12 Chondroitin 4-0- sulfotransferase 2 136213 CHST13 Chondroitin 4-0- sulfotransferase 3 180767 CHST14 Dermatan 169105 CHST15 N- sulfotransferase 1 182022 CHST15 N- sulfotransferase 1 182022 CHST15 N- sulfotransferase 111962 UST DS/CS 2-0 111962 DSE Chondroitin- sulfotransferase 111962 | X:46.43m | 37347 | X: 20.06m | chst7 | 53 | 44341 | 6: 37.57m | chst7 | 13833 | grVIII:17.98m |
| CHOTIC Controline 4-0. 13213 7.2 4 Jun 3661 5. 6 tett 24 3.4.1.2m 6 tri 23 7.392 9401 Indensitience 2 Indensitience 2 Indensitience 2 140.5 In 110.8 In 6 110.2 In 6 110.2 In 6 173 9 10% Indensitience 2 Indensitience 2 Indensitience 2 9 10 In 1 10.8 In 1 10.8 In 9 10% Indensitience 3 Indensitience 3 Indensitience 3 Indensitience 3 9 10 In 1 10.8 In 9 10% Indensitience 3 Indensitience 3 Indensitence 3 Indensitence 3 Indens | CHST12 Chondroitin 4-0- sulfotransferase 2 Infotransferase 3 CHST13 Chondroitin 4-0- sulfotransferase 3 CHST14 Dermatan CHST15 N- CHST15 N- CHST15 N- CHST15 N- CHST15 N- 182022 acetylgalactosamine 4-sulfotransferase 182022 CHST15 N- 182022 Sulfotransferase 182022 CHST15 N- 182022 Sulfotransferase 182022 CHST15 N- 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase Sulfotransferase Sulfotransferase 182022 Sulfotransferase 182022 Sulfotransferase Sulfotransf | 12:104.85m | 34612 | 10: 82.99m | chst11 | 62 | 34375 | 4: 8.24m | chst11 | 19340 | grlV:24.26m |
| Image: control in the contro | CHST13 Chondroitin 4-O- sulfotransferase 3 sulfotransferase 3 CHST14 Dermatan 169105 4-sulfotransferase 1 182022 4-s 6-O- sulfotransferase 111962 UST DS/CS 2-O UST DS/CS 2-O Sulfotransferase Sulfotransferase 111817 | 7:2.44m | 36599 | 5: 140.51m | chst12a | 61 | 28786 | 3: 41.72m | chst12a | 07992 | grXI:4.98m |
| Findencination of the constraint of the con | CHST13 Chondroitin 4-O- sulfotransferase 3 CHST14 Dermatan 4-sulfotransferase 1 CHST15 N- CHST15 N- CHST15 N- 182022 acetylgalactosamine 4-5.0- ulfotransferase UST DS/CS 2-O UST DS/CS 2-O UNDT DS/CS 2-O UNDT DS/CS 2-O UST DS/C | | | | chst12b | . 22 | 77198 | 1: 10.92m | chst12b | 16733 | grlX: 5.13m |
| Image: Sidey Side | CHST13 Chondroitin 4-O- sulfotransferase 3 CHST14 Dermatan 169105 4-sulfotransferase 1 CHST15 N- CHST15 N- CHST15 N- 182022 acetylgalactosamine 4-S 6-O- sulfotransferase UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O Chondroitin- DS/CS 2-O UST DS/CS 2-O Chondroitin- DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O Chondroitin- DS/CS 2-O UST DS/CS 2-O Chondroitin- Chondroitin- DS/CS 2-O DSE Chondroitin- | | | | si:dkey- 26i13.4 | | 94981 | 1: 10.82m | | | |
| Finder Sidery 8636 1:10.00m Finder Sidery 9200 1:10.79m Binder Sidery 9200 1:10.79m Binder Sidery 9200 1:10.79m Binder Sidery 9200 1:10.79m Bindersiderase 3 3:126.24m 5643 5:03.1m 5:0401 Bindersiderase 3 16016 3:126.24m 5603.1m 5:041 23: 0:413 0.4801 Bindersiderase 4 16016 15:40.76m 2418.30m 0:411 23: 0:413 0:4801 9:71 Bindersiderase 4 16916 15:40.76m 2418.30m 0:411 23: 0:413 0:401 9:71 Bindersiderase 4 16916 15:40.76m 2418.30m 0:411 23: 0:411 9:71 Bindersiderase 4 16910 7:132.24m 1:413.77 21:34m 0:411 25:76m 0:413 25:42m 9:71 Bindersiderase 4 1:1962 1:1960 1:113.24m 1:113.24m 1:113.4m 1:113 0:113 0:113 0:113 0:11 | CHST13 Chondroitin 4-O- sulfotransferase 3 CHST14 Dermatan 169105 4-sulfotransferase 1 182022 4-s 6-O- 4-s 6-O- sulfotransferase UST DS/CS 2-O UST DS/CS 2-O UNT DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UNT DS/CS 2-O UST DS/CS 2-O UNT DS/CS 2-O UST DS/CS 2-O UNT DS/CS 2-O UNT DS/CS 2-O UNT DS/CS 2-O UNT DS/CS 2-O UST DS/CS 2-O UNT DS/CS 2-O DS/CS 2-O | | | | si:dkey- 26i13.3 | | 95482 | 1: 10.81m | | | |
| Fields Sickley- 26(13,6) Sickley- 27(13,6) Sickley- 27(13,6) Sickley- 25(13,6) Sickley- 25(13,6) Sickley- 25(13,6) Sickley- 25(13,6) Sickley- 25(13,6) Sickley- 25(13,6) Sickley- 27(13,6) Sick | CHST13 Chondroitin 4-O- sulfotransferase 3 CHST14 Dermatan 4-sulfotransferase 1 4-sulfotransferase 1 2-S 6-O- sulfotransferase UST DS/CS 2-O UST DS/CS 2-O SUlfotransferase DSE Chondroitin- 111817 | | | | si:dkey- 26i13.5 | | 93636 | 1: 10.80m | | | |
| Hertical conditionational conditionational conditionational conditionational conditionational conditionational conditionational conditionational conditionational conditional conditionational conditionational conditionational conditionational conditional conditionational conditionational conditionational conditional conditentente conditional conditional conditional conditional | CHST13 Chondroitin 4-O- sulfotransferase 3 CHST14 Dermatan 4-sulfotransferase 1 182022 4-S 6-O- sulfotransferase UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UST Chondroitin- 111817 DSE Chondroitin- 5 coimerase | | | | si:dkey- 26i13.6 | | 92200 | 1: 10.79m | | | |
| CHST13 Chondrotin 4-0. 180767 3:126.24m 56643 6:90.31m chst13 23: chst13a 10830 g/XV1 Liftotransferase 3 Liftotransferase 3 169105 15:40.76m 74916 21:18.93m chst14 20: chst13b 04801 g/XV1 CHST15 N= 169105 15:40.76m 74916 2:118.93m chst14 50 04811 g/XV1 g/XV1 CHST15 N= 18:002 10:125.77m 30930 7:132.24m chst15 56 74527 17: g/XV1 g/XV1 CHST15 N= 18:2022 10:125.77m 30930 7:132.24m chst15 56 74527 17: 1427 g/XV1 CHST15 N= 18:202 10:125.77m 30930 7:132.24m chst15 56 7457 17: 1427 g/XV1 CHST16 N= 18:202 10:125.77m 30930 7:132.24m chst15 50 7457 17:34m 1427 g/XV1 CHST2 N= 111962 6:149.07m 47712 <t< td=""><td>CHST13 Chondroitin 4-0- sulfotransferase 3 CHST14 Dermatan 4-sulfotransferase 1 182022 4-S 6-0- sulfotransferase 4-S 6-0- sulfotransferase UST DS/CS 2-0 UST DS/CS 2-0 UST DS/CS 2-0 UST Chondroitin- 111817</td><td></td><td></td><td></td><td>si:dkey- 26i13.7</td><td></td><td>92242</td><td>1: 10.78m</td><td></td><td></td><td></td></t<> | CHST13 Chondroitin 4-0- sulfotransferase 3 CHST14 Dermatan 4-sulfotransferase 1 182022 4-S 6-0- sulfotransferase 4-S 6-0- sulfotransferase UST DS/CS 2-0 UST DS/CS 2-0 UST DS/CS 2-0 UST Chondroitin- 111817 | | | | si:dkey- 26i13.7 | | 92242 | 1: 10.78m | | | |
| | CHST14 Dermatan 4-sulfotransferase 1 CHST15 N- CHST15 N- acetylgalactosamine 4-S 6-O- sulfotransferase UST DS/CS 2-O UST DS/CS 2-O UST DS/CS 2-O UIST 01001010 DS/CS 2-O UIST 011062 0 111817 | 3:126.24m | 56643 | 6: 90.31m | chst13 | 52 | 04018 | 23: 34.99m | chst13a | 10830 | grXVII:11.00m |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | CHST14 Dermatan 169105 4-sulfotransferase 1 CHST15 N- 182022 acetylgalactosamine 182022 4-5 6-0- sulfotransferase 111962 UST DS/CS 2-0 111962 UICotransferase 111817 DSE Chondrotitin- 111817 | | | | | | | | chst13b | 04801 | grXII:5.08m |
| CHST15 N- 182022 10:125.77m 3030 7:132.24m chst15 56 7452 17: chst15a 02542 97/1 acetygalactosamine 45.6-0. 11 21.34m 21.34m 21.34m 09700 gr/11 Ust N 11 <td>CHST15 N- 182022 - 182022 - 182022 - 182022 - 182022 - 1826.0-1826.0-1826.0-1926.0-111962 - 111962 - 111962 - 111017 - 111817 - 1</td> <td>15:40.76m</td> <td>74916</td> <td>2:118.93m</td> <td>chst14</td> <td>26</td> <td>43011</td> <td>20: 25.78m</td> <td>chst14</td> <td>14327</td> <td>grVIII:18.79m</td> | CHST15 N- 182022 - 182022 - 182022 - 182022 - 182022 - 1826.0-1826.0-1826.0-1926.0-111962 - 111962 - 111962 - 111017 - 111817 - 1 | 15:40.76m | 74916 | 2:118.93m | chst14 | 26 | 43011 | 20: 25.78m | chst14 | 14327 | grVIII:18.79m |
| Charles Charles Charles 09700 gr/1:1 UST DS/CS 2-0 111962 6:143.07m 47712 10:8.20m ust 67 06044 20:31.45m ust 11589 gr/1:1 Underansferase Underansferase 6:143.07m 47712 10:34.15m ust 20:31.45m ust 11589 gr/1:1 DSE Chondroitin- 111817 6:116.58m 39497 10:34.15m dse 66 17988 20:0.55m dse 06171 gr/Vi DSE Chondroitin- 111817 6:116.58m 39497 10:34.15m dse 66 17988 20:0.55m dse 06171 gr/Vi DSE 5-epimerase 171451 18:65.17m 38702 11:11.86m dsela 62 74504 24:0.05m dsel7 gr/Vi gr/Vi DSE 171451 18:65.17m 38702 11:11.86m dsela 62 74504 24:0.05m dsel7 04870 gr/Vi | UST DS/CS 2-0 111962 0 ulfotransferase 111817 0 DSE Chondroitin- 111817 0 glucuronate | 10:125.77m | 30930 | 7:132.24m | chst15 | 20 | 74527 | 17: 21.34m | chst15a | 02542 | grV:1.18m |
| UST DS/CS 2-0 111962 6:149.07m 47712 10:8.20m ust 67 06044 20:31.45m ust 11589 grXV1 DSE Undransferase Undransferase 06:14.58m 39497 10:34.15m dse 66 17988 20:0.55m dse 06171 grXV1 DSE Chondroitin- 111817 6:16.58m 39497 10:34.15m dse 66 17988 20:0.55m dse 06171 grXV1 DSE T11817 6:16.58m 39497 10:34.15m dse 66 17988 20:0.55m dse 06171 grXV1 DSEL 171451 18:65.17m 38702 11:11.86m dsela 62 74504 dsela 04870 grXV1 | UST DS/CS 2-0 111962 6 ulfotransferase DSE Chondroitin- 111817 glucuronate 5-coimerase | | | | | | | | chst15b | 00260 | grVI:11.74m |
| DSE Chondroitin- 111817 6:116.58m 39497 10:34.15m dse 66 17988 20:0.55m dse 06171 grXVI glucuronate 5-epimerase 1 11.181 8:10.37.15m dse 06.171 9rXVI 9rXVI DSEL 171451 18:65.17m 38702 1:111.86m dsela 62 74504 24:0.05m dsel 04870 9rXXI | DSE Chondroitin- 111817 (glucuronate 5-orimersee | 6:149.07m | 47712 | 10:8.20m | ust | 67 | 06044 | 20:31.45m | ust | 11589 | grXVIII:11.86r |
| DSEL 171451 18:65.17m 38702 1:111.86m dsela 62 74504 24:0.05m dsel 04870 grXXI dsel 04870 grXXI dselb 58 61461 2:27.46m | ט־קטוווקומסס | 6:116.58m | 39497 | 10:34.15m | dse | 66 | 17988 | 20:0.55m | dse | 06171 | grXVIII:3.37m |
| dselb 58 61461 2:27.46m | DSEL 171451 | 18:65.17m | 38702 | 1:111.86m | dsela | 62 | 74504 | 24:0.05m | dsel | 04870 | grXXI:10.44m |
| | | | | | dselb | 58 | 61461 | 2:27.46m | | | |



| Gene | Forward Primer | Reverse Primer |
|---------|--------------------------------------|--------------------------------------|
| chst3a | TGTGGGCGAGTTCTTTAAC | AAGTTTCATGGTCGGTCCAC |
| chst3b | TGTGGCTTTGGTCATCATAGA | GATGAAGCGCATGTGCAG |
| chst7 | ATGAAGAGAAGGCTTCAGAAAAAATACATCATCTTA | TTAGGTCTTCTCCATGTTCCTCTTCTGATAATCCAG |
| chst11 | TGGAGATCCCTTCCAATGAG | CAGGGCTTCAGACCTCAGTC |
| chst12a | TCCTGGAGACCCTCACAATC | TTTGTCTCCAGTGCTCGTTG |
| chst12b | GCAGCTGCAGTTTTTCCTTC | ATGCTCATTGAACGGCTTCT |
| chst13 | AAACAGAAGCGGTTTGTTCTCCG | TCATCTCAACTTCAAGTACGCAGGCAT |
| chst14 | TTTCAAGAAAGCGCAGAAATCAGAGGTT | TAGTGCCTGCAGTATTCAGTGGTTGTGT |
| chst15 | CCACAAGTATGGCCTCCTAAGCT | CACAGAAAAGCAGGGTCCTTTAA |
| dse | TCAGCGTACATGGAGACTCG | GCTGTTAGCATTGTGCCTGA |
| dsela | TGTTTGACTTTGGGGTCACA | CAGGAAGGGCAGCTTTAGTG |
| dselb | AGCTGCCGAATTCAAAAAGA | CTCTGGACCACTCACAAGCA |

Table 2. Primers used to make RNA probes for the in situ hybridization of CS/DS modification enzymes.

doi:10.1371/journal.pone.0121957.t002

Clustal Omega [38]. The default alignment parameters were applied. The sequences were realigned and bootstrapped 1000 times using SEQBOOT from Phylip 3.695v [39]. Protein distances were calculated using PROTDIST. The Jones–Taylor–Thornton matrix was used for the calculation. The neighbor-joining trees were calculated from the 1000 different distance matrixes, previously generated with PROTDIST, using NEIGHBOR from Phylip 3.695. Majority rule consensus tree was constructed with CONSENSE from the same package. The trees were plotted using TreeView 1.6.6 [40].

cDNA cloning

All probes were amplified by PCR from zebrafish cDNA template, transcribed using T7 polymerase and DIG-labeling kit (Roche). Nucleotide removal was performed with the RNeasy kit (Qiagen) and the riboprobes were checked on an agarose gel. Primers for the respective genes are listed in <u>Table 2</u>.

Whole mount in situ hybridization

In situ hybridization was performed essentially as previously described [41]. Zebrafish embryos and larvae of different stages were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS), dehydrated in methanol and stored at-20°C. Upon using, embryos were rehydrated and permeabilized with Proteinase K (5 μ g/ml). Hybridization was performed at 70°C and riboprobes were detected with BM purple AP Substrate precipitating solution (Roche). Embryos and larvae were cleared in glycerol and photographed with a Nikon SMZ1500 Stereomicroscope. Images and figures were adapted in Adobe Photoshop and Adobe Illustrator.

Structural Analysis of CS/DS and HS by Reverse Phase Ion Pair (RPIP)-HPLC

CS/DS and HS were isolated from zebrafish embryos and larvae at different stages in duplicate or triplicate samples with 250 embryos at 30 hpf and 100 embryos at 2 days post fertilization (dpf), 3 dpf and 4 dpf. CS/DS was degraded into disaccharides by enzymatic cleavage, and detected in a HPLC-based system essentially following the protocol as described earlier [42], with the modification of washing the DEAE column with 0.4M NaCl to remove hyaluronic acid. In short, GAGs were isolated by proteolytic cleavage, nuclease treatment, and DEAE ion exchange





Fig 2. Phylogenetic analyses of CS/DS 4-O- and 6-O-sulfotransferases (A) and other CS/DS modification enzymes (B). The consensus neighborjoining trees were calculated with 1000 bootsrap replicates. Zebrafish orthologues are marked with grey shadow. Species names are abbreviated as hs, human; mm, mouse; dr, zebrafish, and ga, stickleback. The accession numbers are listed in the <u>Table 1</u>.

chromatography. The purified GAGs were cleaved with chondroitinase ABC and 10% of the sample was used to identify CS/DS disaccharide components. HS was purified from cleaved CS/DS disaccharides by a second DEAE purifications step followed by cleavage with heparin lysase I-III. The two generated samples of CS/DS and HS disaccharides were subjected to RPIP-HPLC analysis followed by post-column derivatization with cyanoacetamide and detection in a fluorescence detector, essentially as described [42]. The identity and the amount of the disaccharides were established by comparing the samples with CS/DS and HS disaccharide standards, respectively.

Results

Most CS/DS modification enzymes are present as single orthologues in zebrafish

BLAST searches using previously reported amino acid sequences of human and mouse CS/DS modification enzymes [5, 43] as templates were performed to identify orthologous genes in zebrafish (*D. rerio*). Amino acid sequence alignments of identified zebrafish enzymes and human orthologues can be found in <u>S1 Fig.</u> We included another teleost fish, stickleback (*G. aculeatus*), into the analysis in order to better understand the divergence of genes in different teleost lineages after the teleost specific genome duplication. One orthologue of CS/DS 6-*O*-sulfotransferase *CHST7* and two orthologues of CS/DS 6-*O*-sulfotransferases *CHST3*, named *chst3a* and *chst3b*, were identified in both teleost species, sharing 53–58% identity with human proteins (Fig. 2A). Three genes in the group of CS/DS 4-*O*-sulfotransferases *CHST11*, *CHST13* and *CHST14* displayed single orthology to zebrafish genes *chst11*, *chst13* and *chst14*, respective-ly. However, in stickleback two co-orthologues of *CHST13*, *chst13a* and *chst13b* were identified. Zebrafish 4-*O*-sulfotransferases share 52–79% amino acid identity with corresponding human proteins.

Notably, seven sequences show orthology to the human CS/DS 4-O-sulfotransferase *CHST12*. Zebrafish *chst12a* displays 61% identity in protein sequence and is located on chromosome 3, while *chst12b* shares 55% identity with human protein and is located on chromosome 1. The additional five genes are located as tandem copies in close proximity to *chst12b* on chromosome 1 (Table 1). There is evidence for expression of *chst12a* and *chst12b* in zebrafish in the form of pooled RNASEQ data, displayed in the Ensembl database, but no conclusive evidence that the tandem duplicates of *chst12*, named *chst12* (3-, 4-, 5-, 6- and 7), are functional. In stickleback we find two copies of *chst12*, where one is a clear orthologue of zebrafish *chst12a*. With the help of additional analysis of *chst12* genes in other teleosts, we could see a variation in the number of *chst12* gene in gar, a group of fish that diverged prior to the teleost specific genome duplicates.

The human 4-sulfate 6-O-sulfotransferase CHST15 does not belong to the same family as CS/DS 6-O-sulfotransferases. There is one orthologue of human 4-sulfate 6-O-sulfotransferase CHST15 in zebrafish, named *chst15* sharing 56% identical amino acid residues. Other teleosts like stickleback (Fig. 2B), cod, fugu, medaka and platyfish have two co-orthologues of this sulfotransferase gene, named *chst15a* and *chst15b* (data not shown). A single orthologue was identified for CS/DS 2-O-sulfotransferase (ust) in teleosts, where zebrafish *ust* is 67% identical to the human protein sequence. There are two dermatan sulfate epimerase genes in mammals, *DSE* and *DSEL*. Human *DSE* shares 66% amino acid identity with the zebrafish orthologue *dse*. In the zebrafish genome *dsel* seems to be duplicated. *dsela* displays higher identity of the predicted amino acid sequence to the human DSEL (62%) and stickleback dsel (73%) compared to *dselb* (58% and 63%) (Table 1).

CS/DS modification enzymes are spatially and temporally regulated in early zebrafish development

Chondroitin and Dermatan Sulfate 4-O-sulfotransferases. With the exception of *chst11*, all 4-O-sulfotransferases show expression at the 2-cell stage (³/₄ hours post fertilization (hpf)) indicating maternal contribution (Fig. 3). We find that *chst11*, *chst12a* and *chst14* are expressed in the notochord at the somite stages (11–16 hpf) (Fig. 3), in accordance with previously published findings for *chst11* [35]. Staining of *chst11* is shifted from the notochord to the somites, the hindbrain, the midbrain and weak staining is seen in the forebrain at 24 hpf (Fig. 3A). By 36 hpf, the somite expression fades; the forebrain, some cells of the midbrain and the pectoral fin bud show staining, and the hindbrain has a very strong expression (Fig. 3A). At 48 and 60 hpf, the for-, mid- and hindbrain as well as the pectoral fins remain stained and in addition, forming pharyngeal cartilages weakly express chst11 (Fig. 3A). chst12a shows a weak overall expression with stronger expression in the anterior regions at 24 hpf. At 36 hpf, the head and pectoral fins are prominently stained (Fig. 3B). From 48 hpf, chst12a expression is localized to the head, the pectoral fins and the pharyngeal cartilage (Fig. 3B). chst12b shows at the 5- and 15somite stages (11–16 hpf) weak overall expression (Fig. 3C). At 24 hpf, expression becomes stronger in the central nervous system, and at 36 and 48 hpf, the central nervous system and pectoral fins are prominently stained. At 72 hpf, this staining is slightly weaker (Fig. 3C). chst13 displays clear labeling in the somites and the tail bud at 5- and 15-somite stages (11-16 hpf) (Fig. 3D). At 24 hpf, expression in the tail bud, the midbrain-hindbrain boundary (MHB) and a region overlapping with the epiphysis stains (Fig. 3D). By 36 hpf, staining of chst13 is still prominent in the midbrain-hindbrain boundary and the epiphysis, and at 48 and 72 hpf, staining is weak and restricted mainly to the head (Fig. 3D). At 24 hpf, *chst14* displays



Fig 3. Whole mount in situ hybridization of the CS/DS 4-O-sulfotransferases chst11 (A), chst12a (B), chst12b (C), chst13 (D) and chst14 (E). All images, if not otherwise stated in the figure, are shown in lateral views. Arrowheads indicate the position of the transverse section shown in B at 72 hpf. e: epiphysis, hb, hindbrain, mb: midbrain, MHB: midbrain-hindbrain boundary, n: notochord, ov: otic vesicle, pc: pharyngeal cartilage, pf: pectoral fin, s: somites, tb: tailbud

PLOS ONE

strong labeling in the head region and is prominent in the MHB (Fig. 3E). At 48 hpf, strong staining is detected in the pharyngeal cartilage and in the pectoral fins (Fig. 3E).

Chondroitin Sulfate 6-O-sulfotransferases. *chst3a, chst3b* and *chst7* lack staining at the 2-cell stage (¾ hpf) indicating no maternally deposited mRNA (Fig. 4). The *chst3a* probe shows weak overall staining at the 5- and 15-somite stages (11–16 hpf), as well as strong somite staining (Fig. 4A). At 24 and 48 hpf staining is limited to the head and the pectoral fins (at 48 hpf). At 72 hpf, staining is restricted to the pharyngeal cartilages and the pectoral fins (Fig. 4B). At 72 hpf, the pectoral fins show increased staining (Fig. 4B). At 72 hpf, the pectoral fins show increased staining (Fig. 4B). At the 5- and 15-somite stage (11–16 hpf), the *chst7* probe strongly stains the notochord and tail bud (Fig. 4C). At 24 hpf, staining is still detected at the tail bud but starts shifting to the head region where it gets prominent from 36 hpf (Fig. 4C). At 48 and 72 hpf the hindbrain stains strongly as well as the pharyngeal cartilages. (Fig. 4C).

N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase and uronyl-2-sulfotransferase chst15 and *ust* show no staining at the 2-cell stage (³/₄ hpf) indicating no maternal contribution



Fig 4. Whole mount in situ hybridization of the CS/DS 6-O-sulfotransferases chst3a (A), chst3b (B) and chst7 (C). All images show lateral views, if not otherwise stated in the figure. hb: hindbrain, n: notochord, ov: otic vesicle, pc: pharyngeal cartilage, pf: pectoral fin, tb: tailbud, s: somites

doi:10.1371/journal.pone.0121957.g004









(Fig. 5). At the 5-somite stage (11 hpf) *chst15* displays a very distinct staining in a subset of cells in the dorsal midbrain (Fig. 5A). This staining persists at the 15-somite stage (16 hpf), where in addition somites stain strongly (Fig. 5A). At 24 hpf, weak somite staining is still present but fades after this stage (Fig. 5A). The probe for *ust* shows weak overall staining at 5- and 15-somite stages (Fig. 5B). At 24 hpf, weak staining in the head region is observed, while at 48 hpf almost no staining is detected (Fig. 5B).

Dermatan sulfate epimerases. Both probes for *dse* and *dselb* stain at the 2-cell stage ($\frac{3}{4}$ hpf), indicating maternal deposition of mRNA (Fig. 6A,C) while no staining was seen at this stage for *dsela* (Fig. 6B). A general weak staining of *dse* is detected at the 5- and 15-somite stage (11– 16 hpf) while somites and the eyes stain strongly (Fig. 6A). At 24 and 36 hpf, only the posterior end of the somites remain stained and staining appears strong in the most ventral regions of the head (Fig. 6A). At 72 hpf staining is still strong and general in the most ventral regions of the head and pectoral fins (Fig. 6A). *dsela* stains very strong in the polster at the 5-somite stage and shows clear staining in cells of the hatching gland at the 15-somite stage (Fig. 6B). The expression in the hatching gland remains persistent at 24, 36 and 48 hpf, while no staining is detected at 72 hpf (Fig. 6B). *dselb* shows a general expression at the somite stages, and at 24 hpf, somites as well as the head region and the hatching gland are stained (Fig. 6C). At 36 and 48 hpf, in addition to the hatching gland, also the midbrain-hindbrain boundary and the pectoral fins are strongly labeled (Fig. 6C). By 72 hpf, staining is weak and restricted to the pectoral fins and the cartilage elements (Fig. 6C).

Disulfated disaccharides are rare in zebrafish CS/DS. We next investigated the relative sulfation of CS/DS during early zebrafish development. CS/DS was isolated from zebrafish embryos at different developmental stages, cleaved into disaccharides and analyzed by reverse-phase ion-pairing chromatography as previously described [42]. We found that CS/DS sulfation increases from 70 sulfate groups per 100 disaccharides at 30 hpf to 80 sulfate groups 2–4 days post fertilization (dpf) (data not shown). 4-O-sulfate groups are the most common modification (Fig. 7A), in accordance with the strong expression of CS/DS 4-O-sulfotransferases (Fig. 3). The proportion of 6-O-sulfated disaccharides increases from 2dpf (Fig. 7A) correlating with a massive increase in CS/DS synthesis in pharyngeal cartilage [10], suggesting that a high proportion of 6-O-sulfation marks CS/DS synthesis in the cartilage during early zebrafish development. Notably, only low amounts of 2-O-sulfation and disulfated disaccharides could be detected (Fig. 7A), in agreement with the limited spatial expression of the *ust* and *chst15* enzymes (Fig. 5).







PLOS ONE

We next compared the changes in CS/DS modifications to HS. Interestingly, compared to the changes in CS/DS modifications (<u>Fig. 7A</u>), HS modifications remains stable during zebra-fish development (<u>Fig. 7B</u>).

We conclude that CS/DS sulfation during early zebrafish development is a dynamic process dominated by variable proportions of 6-*O*- and 4-*O*-sulfated disaccharides with a marginal contributions of 2-*O*-sulfated and disulfated disaccharides.

Discussion

In this study we present a characterization of what, to the current understanding of CS/DS biosynthesis [2, 4, 5, 43], is the complete set of zebrafish enzymes that modify CS/DS.

The phylogenetic analysis

The zebrafish and stickleback lineages diverged early in teleost evolution but after the teleostspecific genome duplication. Subfunctionalization or neofunctionalization of duplicated genes, or gene loss of one of the duplicates, has occurred both before and after the separation of the





Disaccharide species

Fig 7. Disaccharide composition of CS/DS (A) and HS (B) as measured by RPIP-HPLC analysis. Significant differences (p-value <0.01) in the proportion of specific CS/DS disaccharide species are indicated (star) (A). In contrast, the changes in proportion of specific HS disaccharide species during development between 30 hpf to 4 dpf are not significant (p-value >0.01). (B). Disaccharide species for CS/DS are indicated as 0S CS (ΔHexA-GalNAc/ΔHexA-GlcNAc), 4S (ΔHexA-GalNAc4S), 6S (ΔHexA-GalNAc6S), 2S (ΔHexA2S-GalNAc), 6S4S (ΔHexA-GlcNAc4S6), 4S2S (ΔHexA2S-GalNAc4S), and 6S2S (ΔHexA2S-GalNAc6S). Disaccharide species for HS are indicated as NAc (ΔHexA-GlcNAc), NS (ΔHexA-GlcNAc, NS6S (ΔHexA-GlcNAc6S), 2S (ΔHexA2S-GlcNAc), NS6S (ΔHexA-GlcNAc6S), NS2S (ΔHexA2S-GlcNS), and NS6S2S (ΔHexA2S-GlcNS6S).

doi:10.1371/journal.pone.0121957.g007

two lineages [$\underline{44}$]. Our phylogenetic analysis of CS/DS modification enzymes identified orthologous genes of all mammalian enzymes in the teleosts zebrafish and stickleback (Fig. 2).

We have analyzed the orthologous relationship between human, mouse, stickleback, and zebrafish genes and found that three mammalian genes, *CHST3*, *CHST12*, and *DSEL* are present as duplicates in zebrafish. In comparison, in the stickleback genome, *dsel* is present as a single orthologue and the zebrafish single orthologues *chst13* and *chst15* are duplicated. Our phylogenetic analysis furthermore indicates that the two families of 4-O- and 6-O-sulfotransferases are more similar to each other than to the family of 4-sulfate 6-O-sulfotransferase. This family is represented by a single gene, *CHST15*, in most vertebrates, including zebrafish, whereas some other teleost fishes such as stickleback, medaka and pufferfishes, retain both copies of the gene.

CS/DS biosynthesis is dynamic during embryo development

Our analysis of GAG structures, isolated from whole zebrafish embryos, reveals that CS/DS biosynthesis is dynamic during early zebrafish development compared to an apparent overall stability of HS biosynthesis (Fig. 7). This does not exclude changes in HS structures in certain tissues. The variation of modifications in CS/DS structure during early zebrafish development is characterized by an increase in total sulfation with changes in the proportion of 4-O-sulfated respective 6-O-sulfated disaccharides (Fig. 7A). The shift from 4-O-sulfation to 6-O-sulfation and the relative absence of di-sulfated disaccharides during zebrafish embryogenesis and early larval development are reminiscent of Xenopus laevis development [45]. Evidence has accumulated for interactions between CS/DS and a large number of proteins (reviewed in [2, 4, 5]) and it is an intriguing possibility that CS/DS structure, regulated by combinatorial expression of CS/DS modification enzymes (Fig. <u>3–6</u>), mediates evolutionary conserved instructive functions during animal development. The ratio 4-O-sulfated / 6-O-sulfated disaccharides has also been shown to be crucial during mouse neural development [46]. However, it should be noted that HS disaccharides with multiple sulfate groups, believed to be most important for HS-protein interaction [47], are common during zebrafish development (Fig. 7B). In contrast, CS/DS disaccharides with multiple sulfate groups are rare (Fig. 7A). Also the restricted expression of Chst15 and Ust (Fig. 5), known to be necessary for synthesis of di-sulfated CS/DS disaccharides (reviewed in [5]), suggests that CS/DS disaccharides during zebrafish development are usually decorated with single sulfate groups.

Composition of CS/DS in zebrafish cartilage and bone

CS/DS is accumulated in zebrafish larvae cartilage structures in large amounts [7] and both CS/DS glycosyltransferases [10], 4-O-sulfotransferases (Fig. 3) and 6-O-sulfotransferases (Fig. 4) are distinctly expressed in cartilage structures during zebrafish development. This suggests cartilage CS/DS to be dominated by non-sulfated, 4-O-sulfated and 6-O-sulfated CS/DS disaccharides, also indicated by the whole embryo composition analysis (Fig. 7). These components can further be detected in most cartilage and bone structures by antibodies recognizing CS/DS motifs in zebrafish larvae at 4 dpf and 8 dpf [34] and similar proportions of different CS/DS disaccharides is found in vertebral CS/DS during zebrafish ageing [48].

Cooperation between biosynthesis enzymes

CS/DS biosynthesis enzymes produce tissue specific structures during zebrafish development [34] presumably as a result of differential expression of CS/DS modification enzymes (Figs. 3-6). However, we have previously shown that it is difficult to predict the *in vivo* effect of varying amounts of biosynthesis enzymes, indicating a complex regulation of CS/DS biosynthesis

[7, 49]. Interestingly, evidence has recently accumulated suggesting that cooperation between CS/DS glycosyltransferases and CS/DS modification enzymes strongly affects CS/DS biosynthesis. Expression of CHST11 (C4ST-1) has been shown to be critical for synthesis of long CS/DS chains in mouse fibroblasts [50] and it was further shown that chain elongation by the CS/DS glycosyltransferase CSGALNACT2 depends on CHST11 (C4ST-1) expression [51]. During zebrafish development, such cooperation would be most likely to occur in the notochord and in brain tissue with strong expression of both Csgalnact2 [10] and Chst11 (Fig. 3). In contrast, cooperation between CSGALNACT1 and CHST12 affects CS/DS biosynthesis differently by increasing the number of chains attached to a core protein rather than affecting chain length [52, 53]. While *chst12a* and *chst12b* are widely expressed (Fig. 3), the restricted expression of *csgalnact1* [10] would suggest that such cooperation would be manifested primarily in pharyngeal cartilage structures. Furthermore, the proportion of GlcA to IdoA in CS/DS chains appears to be controlled by functional cooperation between CHST14 (D4ST-1) and DSE (DS-epi1) [54, 55]. chst14 expression is widespread in zebrafish embryos (Fig. 3) while the strong expression of *dse* in pharyngeal cartilage and the notochord suggests that functional collaboration resulting in an elevated proportion of IdoA between these enzymes may occur in these structures (Fig. 6). As only a few studies so far have investigated the role of enzymatic collaboration during CS/DS modification, more examples might well be revealed in future studies. It should also be noted that the role of CS/DS enzymes with the ability to catalyze the same enzymatic reaction is still poorly investigated in organisms. For example, a confirmation of the role for CHST7 in CS/DS biosynthesis during animal development is still lacking.

Conclusions and future directions

In this study we present a detailed phylogenetic analysis of CS/DS modification enzymes and we show that CS/DS modification enzymes are differentially expressed while CS/DS structure varies significantly during zebrafish development. This study together with our previous characterization of zebrafish CS/DS glycosyltransferases [10] thus lay the foundation to design experiments in zebrafish strains with genetically manipulated CS/DS biosynthesis to further understand the regulation of CS/DS biosynthesis, the function of CS/DS modification enzymes and the subsequent effects on embryonic development.

Supporting Information

S1 Fig. Amino acid sequence alignment of the CS/DS modification enzymes in human (hs) and zebrafish (dr) constructed with Clustal Omega. A, alignment of CS/DS 4-*O* sulfotransferases. **B**, CS/DS 6-*O* sulfotransferases. **C**, CS/DS 4-sulfate 6-*O* sulfotransferases. **D**, CS/DS 2-*O*-sulfotransferases and **E**, CS/DS epimerases. Identical amino acids are marked with red letters on yellow background, conserved residues are indicated by blue letters on light blue background and blocks of similar residues marked with black letters on green background. (PDF)

Acknowledgments

We thank professor Lena Kjellén for comments on an earlier version of the manuscript. Zebrafish embryos were provided by the Science for Life Laboratory Zebrafish facility in Uppsala.

Author Contributions

Conceived and designed the experiments: JH KH TD JL. Performed the experiments: JH TH IE KH TD JL. Analyzed the data: JH TH KH JL. Contributed reagents/materials/analysis tools: JH TH IE KH TD PA JL. Wrote the paper: JH TH KH TD PA JL.

References

- 1. Esko JD, Kimata K, Lindahl U. Proteoglycans and Sulfated Glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of Glycobiology. 2nd ed. Cold Spring Harbor (NY)2009.
- Prabhakar V, Sasisekharan R. The biosynthesis and catabolism of galactosaminoglycans. Adv Pharmacol. 2006; 53:69–115. Epub 2007/01/24. [pii] doi: <u>10.1016/S1054-3589(05)53005-9</u> PMID: <u>17239763</u>.
- Maeda N, Ishii M, Nishimura K, Kamimura K. Functions of chondroitin sulfate and heparan sulfate in the developing brain. Neurochem Res. 2010; 36(7):1228–40. Epub 2010/11/27. doi: <u>10.1007/s11064-010-0324-y</u> PMID: <u>21110089</u>.
- Nandini CD, Sugahara K. Role of the sulfation pattern of chondroitin sulfate in its biological activities and in the binding of growth factors. Adv Pharmacol. 2006; 53:253–79. Epub 2007/01/24. [pii] doi: <u>10.</u> <u>1016/S1054-3589(05)53012-6</u> PMID: <u>17239770</u>.
- Mikami T, Kitagawa H. Biosynthesis and function of chondroitin sulfate. Biochimica et biophysica acta. 2013; 1830(10):4719–33. Epub 2013/06/19. doi: <u>10.1016/j.bbagen.2013.06.006</u> PMID: <u>23774590</u>.
- Thelin MA, Bartolini B, Axelsson J, Gustafsson R, Tykesson E, Pera E, et al. Biological functions of iduronic acid in chondroitin/dermatan sulfate. The FEBS journal. 2013; 280(10):2431–46. Epub 2013/ 02/28. doi: <u>10.1111/febs.12214</u> PMID: <u>23441919</u>; PubMed Central PMCID: PMC3717172.
- Holmborn K, Habicher J, Kasza Z, Eriksson AS, Filipek-Gorniok B, Gopal S, et al. On the roles and regulation of chondroitin sulfate and heparan sulfate in zebrafish pharyngeal cartilage morphogenesis. J Biol Chem. 2012; 287(40):33905–16. Epub 2012/08/08. doi: <u>10.1074/jbc.M112.401646</u> PMID: <u>22869369</u>; PubMed Central PMCID: PMC3460485.
- Esko JD, Zhang L. Influence of core protein sequence on glycosaminoglycan assembly. Curr Opin Struct Biol. 1996; 6(5):663–70. Epub 1996/10/01. doi: S0959-440X(96)80034-0 [pii]. PMID: <u>8913690</u>.
- Sugahara K, Kitagawa H. Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr Opin Struct Biol. 2000; 10(5):518–27. Epub 2000/10/24. doi: S0959-440X (00)00125-1 [pii]. PMID: <u>11042448</u>.
- Filipek-Gorniok B, Holmborn K, Haitina T, Habicher J, Oliveira MB, Hellgren C, et al. Expression of chondroitin/dermatan sulfate glycosyltransferases during early zebrafish development. Dev Dyn. 2013; 242(8):964–75. Epub 2013/05/25. doi: <u>10.1002/dvdy.23981</u> PMID: <u>23703795</u>.
- Fukuta M, Kobayashi Y, Uchimura K, Kimata K, Habuchi O. Molecular cloning and expression of human chondroitin 6-sulfotransferase. Biochimica et biophysica acta. 1998; 1399(1):57–61. Epub 1998/08/26. PMID: 9714738.
- Kitagawa H, Fujita M, Ito N, Sugahara K. Molecular cloning and expression of a novel chondroitin 6-Osulfotransferase. The Journal of biological chemistry. 2000; 275(28):21075–80. Epub 2000/04/27. doi: 10.1074/jbc.M002101200 PMID: 10781596.
- Hiraoka N, Nakagawa H, Ong E, Akama TO, Fukuda MN, Fukuda M. Molecular cloning and expression of two distinct human chondroitin 4-O-sulfotransferases that belong to the HNK-1 sulfotransferase gene family. The Journal of biological chemistry. 2000; 275(26):20188–96. Epub 2000/04/27. doi: <u>10.</u> <u>1074/jbc.M002443200</u> PMID: <u>10781601</u>.
- Kang HG, Evers MR, Xia G, Baenziger JU, Schachner M. Molecular cloning and characterization of chondroitin-4-O-sulfotransferase-3. A novel member of the HNK-1 family of sulfotransferases. The Journal of biological chemistry. 2002; 277(38):34766–72. Epub 2002/06/25. doi: <u>10.1074/jbc.</u> M204907200 PMID: 12080076.
- Evers MR, Xia G, Kang HG, Schachner M, Baenziger JU. Molecular cloning and characterization of a dermatan-specific N-acetylgalactosamine 4-O-sulfotransferase. The Journal of biological chemistry. 2001; 276(39):36344–53. Epub 2001/07/27. doi: <u>10.1074/jbc.M105848200</u> PMID: <u>11470797</u>.
- Ohtake S, Ito Y, Fukuta M, Habuchi O. Human N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase cDNA is related to human B cell recombination activating gene-associated gene. The Journal of biological chemistry. 2001; 276(47):43894–900. Epub 2001/09/27. doi: <u>10.1074/jbc.M104922200</u> PMID: <u>11572857</u>.
- 17. Kobayashi M, Sugumaran G, Liu J, Shworak NW, Silbert JE, Rosenberg RD. Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in

dermatan/chondroitin sulfate. The Journal of biological chemistry. 1999; 274(15):10474–80. PMID: 10187838.

- Maccarana M, Olander B, Malmstrom J, Tiedemann K, Aebersold R, Lindahl U, et al. Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is identical to SART2. The Journal of biological chemistry. 2006; 281(17):11560–8. Epub 2006/03/01. doi: <u>10.1074/jbc.M513373200</u> PMID: 16505484.
- Pacheco B, Malmstrom A, Maccarana M. Two dermatan sulfate epimerases form iduronic acid domains in dermatan sulfate. The Journal of biological chemistry. 2009; 284(15):9788–95. Epub 2009/02/04. doi: <u>10.1074/jbc.M809339200</u> PMID: <u>19188366</u>; PubMed Central PMCID: PMC2665100.
- Mizumoto S, Ikegawa S, Sugahara K. Human genetic disorders caused by mutations in genes encoding biosynthetic enzymes for sulfated glycosaminoglycans. The Journal of biological chemistry. 2013; 288(16):10953–61. doi: <u>10.1074/jbc.R112.437038</u> PMID: <u>23457301</u>; PubMed Central PMCID: PMC3630846.
- Mizumoto S, Yamada S, Sugahara K. Human genetic disorders and knockout mice deficient in glycosaminoglycan. BioMed research international. 2014; 2014:495764. doi: <u>10.1155/2014/495764</u> PMID: <u>25126564</u>; PubMed Central PMCID: PMC4122003.
- Thiele H, Sakano M, Kitagawa H, Sugahara K, Rajab A, Hohne W, et al. Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101 (27):10155–60. Epub 2004/06/25. doi: <u>10.1073/pnas.0400334101</u> PMID: <u>15215498</u>; PubMed Central PMCID: PMC454181.
- Unger S, Lausch E, Rossi A, Megarbane A, Sillence D, Alcausin M, et al. Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features. American journal of medical genetics Part A. 2010; 152A (10):2543–9. Epub 2010/09/11. doi: 10.1002/ajmg.a.33641 PMID: 20830804.
- Bartolini B, Thelin MA, Rauch U, Feinstein R, Oldberg A, Malmstrom A, et al. Mouse development is not obviously affected by the absence of dermatan sulfate epimerase 2 in spite of a modified brain dermatan sulfate composition. Glycobiology. 2012; 22(7):1007–16. doi: <u>10.1093/glycob/cws065</u> PMID: <u>22496542</u>.
- Malfait F, Syx D, Vlummens P, Symoens S, Nampoothiri S, Hermanns-Le T, et al. Musculocontractural Ehlers-Danlos Syndrome (former EDS type VIB) and adducted thumb clubfoot syndrome (ATCS) represent a single clinical entity caused by mutations in the dermatan-4-sulfotransferase 1 encoding CHST14 gene. Human mutation. 2010; 31(11):1233–9. Epub 2010/09/16. doi: <u>10.1002/humu.21355</u> PMID: <u>20842734</u>.
- Muller T, Mizumoto S, Suresh I, Komatsu Y, Vodopiutz J, Dundar M, et al. Loss of dermatan sulfate epimerase (DSE) function results in musculocontractural Ehlers-Danlos syndrome. Human molecular genetics. 2013; 22(18):3761–72. Epub 2013/05/25. doi: <u>10.1093/hmg/ddt227</u> PMID: <u>23704329</u>.
- Maccarana M, Kalamajski S, Kongsgaard M, Magnusson SP, Oldberg A, Malmstrom A. Dermatan sulfate epimerase 1-deficient mice have reduced content and changed distribution of iduronic acids in dermatan sulfate and an altered collagen structure in skin. Molecular and cellular biology. 2009; 29 (20):5517–28. Epub 2009/08/19. doi: <u>10.1128/MCB.00430-09</u> PMID: <u>19687302</u>; PubMed Central PMCID: PMC2756890.
- Reynard LN, Loughlin J. The genetics and functional analysis of primary osteoarthritis susceptibility. Expert reviews in molecular medicine. 2013; 15:e2. doi: <u>10.1017/erm.2013.4</u> PMID: <u>23414786</u>; PubMed Central PMCID: PMC3575889.
- Kluppel M, Wight TN, Chan C, Hinek A, Wrana JL. Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development. 2005; 132(17):3989–4003. Epub 2005/08/05. doi: <u>10.</u> <u>1242/dev.01948</u> PMID: <u>16079159</u>.
- Ohtake-Niimi S, Kondo S, Ito T, Kakehi S, Ohta T, Habuchi H, et al. Mice deficient in N-acetylgalactosamine 4-sulfate 6-o-sulfotransferase are unable to synthesize chondroitin/dermatan sulfate containing N-acetylgalactosamine 4,6-bissulfate residues and exhibit decreased protease activity in bone marrowderived mast cells. The Journal of biological chemistry. 2010; 285(27):20793–805. Epub 2010/05/05. doi: 10.1074/jbc.M109.084749 PMID: 20439988; PubMed Central PMCID: PMC2898370.
- Kluppel M, Vallis KA, Wrana JL. A high-throughput induction gene trap approach defines C4ST as a target of BMP signaling. Mechanisms of development. 2002; 118(1–2):77–89. Epub 2002/09/28. PMID: 12351172.
- Diez-Roux G, Banfi S, Sultan M, Geffers L, Anand S, Rozado D, et al. A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS biology. 2011; 9(1):e1000582. Epub 2011/01/27. doi: <u>10.1371/journal.pbio.1000582</u> PMID: <u>21267068</u>; PubMed Central PMCID: PMC3022534.

- van der Zwaag B, Burbach JP, Scharfe C, Oefner PJ, Brunner HG, Padberg GW, et al. Identifying new candidate genes for hereditary facial paresis on chromosome 3q21-q22 by RNA in situ hybridization in mouse. Genomics. 2005; 86(1):55–67. Epub 2005/06/15. doi: <u>10.1016/j.ygeno.2005.03.007</u> PMID: <u>15953540</u>.
- Hayes AJ, Mitchell RE, Bashford A, Reynolds S, Caterson B, Hammond CL. Expression of glycosaminoglycan epitopes during zebrafish skeletogenesis. Developmental dynamics: an official publication of the American Association of Anatomists. 2013; 242(6):778–89. doi: <u>10.1002/dvdy.23970</u> PMID: <u>23576310</u>; PubMed Central PMCID: PMC3698701.
- Mizumoto S, Mikami T, Yasunaga D, Kobayashi N, Yamauchi H, Miyake A, et al. Chondroitin 4-O-sulfotransferase-1 is required for somitic muscle development and motor axon guidance in zebrafish. Biochem J. 2009; 419(2):387–99. Epub 2009/01/08. doi: BJ20081639 [pii] doi: <u>10.1042/BJ20081639</u> PMID: <u>19125692</u>.
- Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Developmental dynamics: an official publication of the American Association of Anatomists. 1995; 203(3):253–310. Epub 1995/07/01. doi: 10.1002/aja.1002030302 PMID: 8589427.
- Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, et al. Ensembl 2013. Nucleic acids research. 2013; 41(Database issue):D48–55. Epub 2012/12/04. doi: <u>10.1093/nar/gks1236</u> PMID: <u>23203987</u>; PubMed Central PMCID: PMC3531136.
- Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular systems biology. 2011; 7:539. Epub 2011/10/13. doi: <u>10.1038/msb.2011.75</u> PMID: <u>21988835</u>; PubMed Central PMCID: PMC3261699.
- 39. Felsenstein J. PHYLIP—Phylogeny Interference Package (Version 3.2). Cladistics. 1989; 5:164–6.
- Page RD. TreeView: an application to display phylogenetic trees on personal computers. Computer applications in the biosciences: CABIOS. 1996; 12(4):357–8. Epub 1996/08/01. PMID: <u>8902363</u>.
- Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat Protoc. 2008; 3(1):59–69. Epub 2008/01/15. doi: nprot.2007.514 [pii] doi: <u>10.1038/nprot.2007.514</u> PMID: 18193022.
- Ledin J, Staatz W, Li JP, Gotte M, Selleck S, Kjellen L, et al. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem. 2004; 279(41):42732–41. PMID: 15292174.
- Kusche-Gullberg M, Kjellen L. Sulfotransferases in glycosaminoglycan biosynthesis. Current opinion in structural biology. 2003; 13(5):605–11. Epub 2003/10/22. PMID: <u>14568616</u>.
- Hoegg S, Brinkmann H, Taylor JS, Meyer A. Phylogenetic timing of the fish-specific genome duplication correlates with the diversification of teleost fish. Journal of molecular evolution. 2004; 59(2):190–203. Epub 2004/10/16. doi: 10.1007/s00239-004-2613-z PMID: 15486693.
- Yamada S, Onishi M, Fujinawa R, Tadokoro Y, Okabayashi K, Asashima M, et al. Structural and functional changes of sulfated glycosaminoglycans in Xenopus laevis during embryogenesis. Glycobiology. 2009; 19(5):488–98. Epub 2009/02/05. doi: cwp005 [pii] doi: <u>10.1093/glycob/cwp005</u> PMID: <u>19190026</u>.
- Miyata S, Komatsu Y, Yoshimura Y, Taya C, Kitagawa H. Persistent cortical plasticity by upregulation of chondroitin 6-sulfation. Nat Neurosci. 2012; 15(3):414–22, S1–2. doi: <u>10.1038/nn.3023</u> PMID: <u>22246436</u>.
- Kreuger J, Spillmann D, Li JP, Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol. 2006; 174(3):323–7. Epub 2006/08/02. doi: jcb.200604035 [pii] doi: <u>10.</u> <u>1083/jcb.200604035</u> PMID: <u>16880267</u>.
- Hayes AJ, Reynolds S, Nowell MA, Meakin LB, Habicher J, Ledin J, et al. Spinal Deformity in Aged Zebrafish Is Accompanied by Degenerative Changes to Their Vertebrae that Resemble Osteoarthritis. PloS one. 2013; 8(9):e75787. Epub 2013/10/03. doi: <u>10.1371/journal.pone.0075787</u> PMID: <u>24086633</u>; PubMed Central PMCID: PMC3782452.
- Ledin J, Ringvall M, Thuveson M, Eriksson I, Wilen M, Kusche-Gullberg M, et al. Enzymatically active N-deacetylase/N-sulfotransferase-2 is present in liver but does not contribute to heparan sulfate N-sulfation. J Biol Chem. 2006; 281(47):35727–34. Epub 2006/09/21. doi: <u>10.1074/jbc.M604113200</u> PMID: <u>16984905</u>.
- Uyama T, Ishida M, Izumikawa T, Trybala E, Tufaro F, Bergstrom T, et al. Chondroitin 4-O-sulfotransferase-1 regulates E disaccharide expression of chondroitin sulfate required for herpes simplex virus infectivity. J Biol Chem. 2006; 281(50):38668–74. Epub 2006/10/17. doi: M609320200 [pii] doi: <u>10.1074/</u> jbc.M609320200 PMID: <u>17040900</u>.
- Izumikawa T, Okuura Y, Koike T, Sakoda N, Kitagawa H. Chondroitin 4-O-sulfotransferase-1 regulates the chain length of chondroitin sulfate in co-operation with chondroitin N-

acetylgalactosaminyltransferase-2. The Biochemical journal. 2011; 434(2):321–31. Epub 2010/12/09. doi: 10.1042/BJ20101456 PMID: 21138417.

- Izumikawa T, Koike T, Kitagawa H. Chondroitin 4-O-sulfotransferase-2 regulates the number of chondroitin sulfate chains initiated by chondroitin N-acetylgalactosaminyltransferase-1. The Biochemical journal. 2012; 441(2):697–705. Epub 2011/09/29. doi: <u>10.1042/BJ20111472</u> PMID: <u>21942880</u>.
- Sakai K, Kimata K, Sato T, Gotoh M, Narimatsu H, Shinomiya K, et al. Chondroitin sulfate N-acetylgalactosaminyltransferase-1 plays a critical role in chondroitin sulfate synthesis in cartilage. The Journal of biological chemistry. 2007; 282(6):4152–61. Epub 2006/12/06. doi: <u>10.1074/jbc.M606870200</u> PMID: <u>17145758</u>.
- 54. Malmstrom A, Fransson LA. Biosynthesis of dermatan sulfate. I. Formation of L-iduronic acid residues. J Biol Chem. 1975; 250(9):3419–25. PMID: <u>1123348</u>.
- Pacheco B, Maccarana M, Malmstrom A. Dermatan 4-O-sulfotransferase 1 is pivotal in the formation of iduronic acid blocks in dermatan sulfate. Glycobiology. 2009; 19(11):1197–203. Epub 2009/08/08. doi: <u>10.1093/glycob/cwp110</u> PMID: <u>19661164</u>.